Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Has signed the Informed Consent From (ICF) and is able to read and understand the information provided in the ICF.~2. Is 22 to 65 years of age (inclusive) at screening.~3. Smokes an average of at least 10 commercially available cigarettes per day and has done so for the last 12 months.~4. Expired air CO reading of at least 10 ppm as assessed at the screening session.~5. Interested in switching to an electronic cigarette or nicotine pouch.~6. Willing and able to comply with the requirements of the study.~7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.~Exclusion Criteria:~1. Any participant who has a medical or physical condition that, in the opinion of the investigator (or designee), may adversely affect participant safety, the safety of others, or data validity.~2. Planned use of an FDA-approved smoking cessation product during the study, not provided as part of this protocol.~3. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.~4. Taking psychoactive medications (e.g., antipsychotics, benzodiazepines, or mood stabilizers).~5. Frequent users (monthly) of smokeless tobacco (chewing tobacco, snuff), cigars (not cigarillos), pipes, hookahs or other non-commercially available combustible or heated tobacco products.~6. Use of nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.~7. Pregnant or nursing (by self-report) or positive pregnancy test.~8. Heterosexually active participant of Childbearing Potential (not sterilized by tubal ligation, oophorectomy, hysterectomy, or other surgical methods, or post-menopausal) that do not agree to practice medically appropriate methods of birth control (or remain abstinent) during the course of the trial. Medically acceptable methods of birth control include: successful vasectomy of male partner, vaginal diaphragm with spermicide, intrauterine device, hormonal birth control (oral, injected, or implanted), condom with spermicide, or sponge with spermicide.~9. Participants who were enrolled in a clinical trial within 30 days of screening.~10. Enrollment numbers met (in sub-group or entire study).

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group I - NRT Responder (Type: EXPERIMENTAL): Participants that were successful in quitting smoking using NRT in the first four weeks of the study will have the option of remaining on their current NRT or switching to one of the other two options for the next five weeks.
- Group IIa NRT Non-Responder - Pouch Preferrers (Type: EXPERIMENTAL): Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be switched to nicotine pouch for the next five weeks.
- Group IIb NRT Non-Responder - Pouch Preferrers Control (Type: EXPERIMENTAL): Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be remain on NRT for the next five weeks.
- Group IIIa NRT Non-Responder - ENDS Preferrers (Type: EXPERIMENTAL): Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be switched to ENDS for the next five weeks.
- Group IIIb NRT Non-Responder - ENDS Preferrers Control (Type: EXPERIMENTAL): Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be remain on NRT for the next five weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).